###begin article-title 0
Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
The alanine allele of P12A polymorphism in PPARG gene in a few studies has been associated with a reduced or increased risk of acute myocardial infarction (AMI). Yet, the risk relation has not been confi rmed, and data on ischemic stroke (IS) is scarce. We therefore investigated the role of this polymorphism on occurrence of AMI, coronary heart disease (CHD) and IS.
###end p 2
###begin title 3
Methods and fi ndings
###end title 3
###begin p 4
###xml 67 72 <span type="species:ncbi:9606">women</span>
We performed a case-cohort study in 15,236 initially healthy Dutch women and applied a Cox proportional hazards model to study the relation of the P12A polymorphism and AMI (n = 71), CHD (n = 211), and IS (n = 49) under different inheritance models. In addition, meta-analyses of published studies were performed. Under the dominant inheritance model, carriers of the alanine allele compared with those with the more common genotype were not at increased or decreased risk of CHD (hazard ratio [HR] = 0.82; 95% confi dence interval [CI], 0.58 to 1.17) and of IS (HR = 1.03; 95% CI, 0.14 to 7.74). In addition no relations were found under the recessive and additive models. Our meta-analyses corroborated these fi ndings by showing no signifi cant association. For AMI we found a borderline signifi cant association under dominant (HR = 0.49; 95% CI, 0.26 to 0.94), and additive (HR = 0.51; 95% CI, 0.26 to 1.00) models which could be due to chance, because of small cases in this subgroup. The meta-analysis did not show any association between the polymorphism and risk of AMI under the different genetic models.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 27 32 <span type="species:ncbi:9606">women</span>
Our study in healthy Dutch women in combination with the meta-analyses of previous reports does not provide support for a role of P12A polymorphism in PPARG gene in MI and CHD risk. Also our study shows that the polymorphism has no association with IS risk.
###end p 6
###begin title 7
Introduction
###end title 7
###begin p 8
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 118 140 118 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Knouff and Auwerx 2004</xref>
###xml 213 245 213 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Temelkova-Kurktschiev et al 2004</xref>
###xml 428 448 428 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Schiffrin et al 2003</xref>
###xml 450 468 450 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Youssef et al 2004</xref>
###xml 573 593 573 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Memisoglu et al 2003</xref>
###xml 19 24 <span type="species:ncbi:9606">human</span>
The most prevalent human PPARG gene mutation is a cytosine to guanine substitution in exon B (codon 12) of this gene (Knouff and Auwerx 2004), resulting in an exchange of proline (P) to alanine (A) at amino acid (Temelkova-Kurktschiev et al 2004). Initially recognized to play a role only in adipogenesis and glucose homeostasis, recent works have shown associations with regulation of cell growth, migration and infl ammation (Schiffrin et al 2003; Youssef et al 2004). Also, PPARG2 has a role in insulin signaling, insulin resistance, and development of type 2 diabetes (Memisoglu et al 2003).
###end p 8
###begin p 9
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 97 112 97 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Deeb et al 1998</xref>
###xml 114 134 114 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Altshuler et al 2000</xref>
###xml 136 157 136 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Meirhaeghe et al 2000</xref>
###xml 159 176 159 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Masud and Ye 2003</xref>
###xml 178 196 178 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Ostgren et al 2003</xref>
###xml 198 214 198 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Doney et al 2004</xref>
###xml 284 304 284 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Altshuler et al 2000</xref>
###xml 387 404 387 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Masud and Ye 2003</xref>
###xml 433 448 433 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Deeb et al 1998</xref>
###xml 450 471 450 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Meirhaeghe et al 2000</xref>
###xml 501 519 501 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Ostgren et al 2003</xref>
###xml 521 537 521 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Doney et al 2004</xref>
###xml 741 773 741 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Temelkova-Kurktschiev et al 2004</xref>
There is some evidence that P12A polymorphism in PPARG gene is related to vascular risk factors (Deeb et al 1998; Altshuler et al 2000; Meirhaeghe et al 2000; Masud and Ye 2003; Ostgren et al 2003; Doney et al 2004). A meta-analysis showed a 21% risk reduction for type2 of diabetes (Altshuler et al 2000). Moreover, A12 allele carriers have signifi cantly higher body mass index (BMI) (Masud and Ye 2003), lower insulin resistance (Deeb et al 1998; Meirhaeghe et al 2000) and reduced blood pressure (Ostgren et al 2003; Doney et al 2004). These fi ndings suggest that a possible role in atherosclerosis development. This is supported by recent fi ndings showing a relation of A12A genotype to reduced common carotid intima-media thickness (Temelkova-Kurktschiev et al 2004; Al Shali et al 2004b).
###end p 9
###begin p 10
###xml 186 200 186 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Vos et al 2000</xref>
###xml 202 219 202 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Ridker et al 2003</xref>
###xml 221 237 221 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Doney et al 2004</xref>
###xml 239 255 239 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Tobin et al 2004</xref>
###xml 257 275 257 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Pischon et al 2005</xref>
###xml 277 290 277 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Li et al 2006</xref>
###xml 355 369 355 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Lee et al 2006</xref>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 513 518 <span type="species:ncbi:9606">women</span>
However, information on the relation with acute myocardial infarction (AMI), coronary heart disease (CHD) and ischemic stroke (IS) as the clinical endpoints is scarce, and inconsistent (Vos et al 2000; Ridker et al 2003; Doney et al 2004; Tobin et al 2004; Pischon et al 2005; Li et al 2006) for CHD. A reduced risk for ischemic stroke has been reported (Lee et al 2006). We set out to investigate the relation of P12A polymorphism in PPARG gene on occurrence of AMI, CHD and ischemic stroke in middle-aged Dutch women. To expand the evidence further, we performed meta-analyses using published data from observational studies.
###end p 10
###begin title 11
Methods
###end title 11
###begin title 12
Prospect-EPIC study
###end title 12
###begin p 13
###xml 121 145 121 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Zafarmand et al in Press</xref>
###xml 192 204 <span type="species:ncbi:9606">participants</span>
###xml 234 246 <span type="species:ncbi:9606">Participants</span>
###xml 290 295 <span type="species:ncbi:9606">women</span>
###xml 421 426 <span type="species:ncbi:9606">women</span>
###xml 1051 1056 <span type="species:ncbi:9606">women</span>
Study design, general questionnaire, anthropometric and Laboratory measurements have been described in detail elsewhere (Zafarmand et al in Press). Briefl y, the study population consisted of participants of the Prospect-EPIC cohort. Participants were recruited between 1993 and 1997 among women living in Utrecht and vicinity who attended the regional population-based breast cancer-screening program. A total of 17,357 women aged 49-70 were included. Follow-up event information was obtained from the Dutch Centre for Health Care Information, which holds a standardized computerized register of hospital discharge diagnoses. Using the International Classifi cation of Diseases, ninth Revision (ICD-9) codes for the main discharge reason, we categorized cardiovascular disease (codes 390-459) as CHD (codes 410-414), including acute myocardial infarction (code 410), as ischemic cerebrovascular disease (codes 433-435), and other cardiovascular diseases. Whenever multiple events occurred, the fi rst diagnosis was taken as endpoint of interest. All women signed an informed consent form prior to study inclusion. The study was approved by the Institutional Review Board of the University Medical Center Utrecht.
###end p 13
###begin p 14
###xml 48 63 48 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Prentice (1986)</xref>
###xml 351 356 <span type="species:ncbi:9606">women</span>
###xml 378 383 <span type="species:ncbi:9606">Women</span>
###xml 521 526 <span type="species:ncbi:9606">Women</span>
###xml 702 707 <span type="species:ncbi:9606">women</span>
###xml 737 742 <span type="species:ncbi:9606">women</span>
We applied the case-cohort design introduced by Prentice (1986). In this design, data is collected on all subjects, but the data would only be analyzed on cases and sub-cohort members. Cases are those emerging in the total cohort; controls are subjects in the sub-cohort. The sub-cohort is a randomly selected sample of 10% (n = 1736) from the 17,357 women in the total cohort. Women who did not consent to linkage with vital status registries or who were not traceable (cases n = 3/sub-cohort n = 38) were not included. Women who reported a diagnosis of cardiovascular disease (ICD-9; 390-459) at baseline, who had missing questionnaires or blood or DNA samples were excluded. This resulted in 15,236 women in the total cohort and 1519 women in the sub-cohort at baseline (as the control group). All fi rst fatal and non-fatal CHD and ischemic stroke events that arose during follow-up until January 1st 2000 were selected as cases. These were 211 CHD cases, including 71 AMIs, and 49 ischemic cerebrovascular events. For all case subjects follow up ended at the date of diagnosis or at the date of death due to cardiovascular disease.
###end p 14
###begin title 15
Genetic analysis
###end title 15
###begin p 16
###xml 229 232 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 473 489 471 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Cheng et al 1999</xref>
Genetic analysis was performed at the Cardiovascular Genotyping (CAGT) laboratory of the Department of Internal Medicine of the University Hospital Maastricht. Genomic DNA was extracted from buffy coats with the use of the QIAamp(R) Blood Kit (Qiagen Inc., Valencia, California, USA). Genotyping of the polymorphisms was performed using a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Pleasanton, CA, USA) (Cheng et al 1999). Genotyping was preformed blinded to the case-control status. A random double-check was performed to detect potential genotyping errors.
###end p 16
###begin title 17
Data analysis
###end title 17
###begin p 18
To assess the relation of P12A polymorphism with the outcome, we used a Cox proportional hazards model with an estimation procedure adapted for case-cohort designs. We used the unweighted method by Prentice, which is incorporated in a SAS macro at .
###end p 18
###begin p 19
###xml 143 144 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Baseline characteristics of sub-cohort by genotypes (P12P, P12A and A12A) is given. Hardy-Weinberg equilibrium (HWE) was evaluated with the chi2 test. Frequencies of A12 allele and P12 allele were determined. We assessed the association between the polymorphism and events under different genetic models. The dominant genetic model compares individuals with one or more polymorphic alleles (P12A and A12A genotypes combined) with a group with no polymorphic alleles (P12P). The recessive genetic model compares the A12A genotype with the combined P12P and P12A genotypes. The additive genetic model assumes that there is a linear gradient in risk between the P12P, P12A and A12A genotypes (P12P genotype baseline). This is equivalent to a comparison of the A12 allele versus the P12 allele (baseline). All analyses were performed for AMI, CHD, ischemic stroke and total ischemic events. A value of p < 0.05 (2-sided) was considered signifi cant.
###end p 19
###begin title 20
Meta-analysis
###end title 20
###begin title 21
Search strategy and data extraction
###end title 21
###begin p 22
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1747 1754 1747 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 1760 1789 1760 1789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Pischon and colleagues (2005)</xref>
###xml 839 844 <span type="species:ncbi:9606">human</span>
###xml 1866 1871 <span type="species:ncbi:9606">women</span>
###xml 1923 1926 <span type="species:ncbi:9606">men</span>
For the meta-analysis, published data was used concerning the P12A polymorphism in PPARG gene and MI, CHD and IS. The search was done on November 15, 2006. In addition, our own data were included. Studies were found with PubMed/Medline, ISI Web of Knowledge, and Embase using the following text search string: (Pro12Ala OR P12A) AND ("Peroxisome proliferator-activated receptor gamma" OR PPARG) AND (coronary disease OR coronary heart disease OR CHD OR myocardial infarction OR MI OR myocardial infarct OR coronary artery disease OR CAD OR ischemic heart disease OR IHD OR cardiovascular disease OR heart disease OR angina OR ischemic stroke OR CVA OR stroke OR cerebrovascular accident). The following constraints were applied to the search: (1) only published articles in journals or their supplements (English); and (2) studies only in human subjects. Manual bibliography review was added. This search (done by MHZ and MLB) identifi ed 36 potentially relevant articles. Studies were included if they reported the relative risks, ORs or HRs and 95% confi dence intervals [CIs] for events related to PPARG2 P12A polymorphism or provided raw data that allowed estimation of these values. We excluded 24 studies because of other endpoints (such as vascular risk factors); one repeated publication; one study which did not provide suffi cient data; two review papers; and one study with carotid intima-media thickness as endpoint. Since only one paper had been found for ischemic stroke, we excluded ischemic stroke from the meta-analysis. Hence, data were available for these analyses from 8 original reports (6 studies found with databases, one additional article identifi ed by a hand search and our data) involving 2793 cases and 7680 controls (Table 4). As Pischon and colleagues (2005) had provided data from two different studies (Nurses' Health Study [NHS] in women and Health Professionals Follow-up Study [HPFS] in men), we consider them in the analysis as two studies. The following information was extracted from each study: fi rst author, study design, year of publication, geographical location, defi nition and number of cases and controls, mean age of cases and controls, gender, genotype frequency, genotyping methods and consistency of genotype frequencies with Hardy-Weinberg equilibrium.
###end p 22
###begin p 23
Characteristics of studies included in the meta - analysis
###end p 23
###begin p 24
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CHD, coronary heart disease; MI, myocardial infarction; HWE, Hardy - Weinberg equilibrium.
###end p 24
###begin p 25
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes: Range of age (year).
###end p 25
###begin title 26
Data analysis
###end title 26
###begin p 27
###xml 307 308 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 351 372 349 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Trikalinos et al 2006</xref>
###xml 451 465 447 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Lau et al 1997</xref>
###xml 530 531 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 531 532 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 593 594 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 594 595 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 904 922 900 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Higgins et al 2003</xref>
For the meta-analysis, Mantel-Haenszel was used as fi xed effects model and the DerSimonian-Laird method was used as random-effects model, all under different genetic models. The Egger's test with 95% CI was used for evaluating publication bias. In each study, we tested for HWE by using an asymptomatic chi2 test or an exact test among the controls (Trikalinos et al 2006). We used Cochran's chi2 - based Q statistic for between-study heterogeneity (Lau et al 1997), which is considered signifi cant for p < 0.10, as well as the I2 statistic for estimation of inconsistency in meta-analyses. I2 represents the percentage of the observed between-study variability due to heterogeneity rather than to chance and ranges from 0 to 100 percent where a value of 0% indicates no observed heterogeneity, and larger values an increasing degree of heterogeneity. Values above 75 percent imply high heterogeneity (Higgins et al 2003). Meta-analysis was carried out using STATA 9.1.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Prospect-EPIC study results
###end title 29
###begin p 30
###xml 99 106 99 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 48 60 <span type="species:ncbi:9606">participants</span>
###xml 115 127 <span type="species:ncbi:9606">participants</span>
General characteristics of the randomly sampled participants of the cohort (n = 1519) are given in Table 1. Of the participants 1143 (75.2%) had the common type allele (P12P), 346 (22.8%) were heterozygous for the A12 allele (P12A), and 30 (2%) were homozygous for the A12 allele. The genotype distribution was in HWE.
###end p 30
###begin p 31
Baseline characteristics of the sub-cohort according to genotype, and clinical characteristics of CHD cases and controls in the Prospect - Epic cohort
###end p 31
###begin p 32
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
Notes:
###end p 32
###begin p 33
Mean +/- standard deviation;
###end p 33
###begin p 34
###xml 102 103 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Comparison of risk factors across genotypes, using the ANOVA F test (continuous variables) and the chi2 statistic (categorical variables);
###end p 34
###begin p 35
###xml 60 86 60 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">independent samples t-test</italic>
###xml 121 122 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Comparison of risk factors across disease status, using the independent samples t-test (continuous variables) and the chi2 statistic (categorical variables);
###end p 35
###begin p 36
Defi ned as a systolic blood pressure >/=140 mm Hg and/or diastolic blood pressure >/=90 mm Hg and/or questionnaire positive;
###end p 36
###begin p 37
###xml 76 82 <span type="species:ncbi:9606">person</span>
The number of packs of cigarettes smoked per day by the number of years the person has smoked.
###end p 37
###begin p 38
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410-414).
###end p 38
###begin p 39
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 502 509 502 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 190 196 <span type="species:ncbi:9606">person</span>
###xml 258 263 <span type="species:ncbi:9606">women</span>
###xml 275 281 <span type="species:ncbi:9606">person</span>
###xml 323 328 <span type="species:ncbi:9606">women</span>
None of conventional risk factors were statistically signifi cantly related to the P12A polymorphism (Table 1). Median follow up time for the sub-cohort was 4.3 years, with a total of 6,525 person years. The actual follow-up in the baseline cohort of 15,236 women was 64,768 person years. Due to the case-cohort design, 23 women in the sub-cohort eventually were CHD cases and 5 of them were ischemic stroke cases (totally 28 cases). Clinical characteristics of CHD cases and controls are presented in Table 1.
###end p 39
###begin p 40
###xml 202 209 202 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
Comparing allele frequencies in cases and control groups separately did not show signifi cant difference between them, except for myocardial infarction, which showed a borderline signifi cant relation (Table 2).
###end p 40
###begin p 41
Genotype and allele frequencies of the polymorphism among AMI, CHD, and ischemic stroke cases and sub-cohort of the Prospect - Epic cohort
###end p 41
###begin p 42
###xml 224 231 224 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 458 465 458 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 553 560 553 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 988 1010 988 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Smith and Ebrahim 2004</xref>
A lower risk of AMI with only borderline effects was found under dominant (OR = 0.51; 95% CI, 0.26 to 1.00; p = 0.05) and additive models (OR = 0.49; 95% CI, 0.26 to 0.94; p = 0.03) but not under recessive inheritance mode (Table 3). The analyses were repeated for CHD and ischemic stroke as primary outcomes and also for all ischemic events (CHD and ischemic stroke). No statistically signifi cant association was seen for risks of CHD and ischemic stroke (Table 3). None of the risk factors was statistically signifi cantly associated with genotypes (Table 1) and we did not consider them as confounders in our data. The rationale for not adjusting for the risk factors is that we did not want to adjust in a primary analysis for intermediates in a potential causal pathway and that because genes are randomly assigned at conception (Mendelian randomization) confounding by lifestyle related factors (or intermediate phenotypes) should not be a problem in genetic epidemiology studies (Smith and Ebrahim 2004).
###end p 42
###begin p 43
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Hazard ratios of cardiovascular events under different genetic models for P12A polymorphism in PPARG gene in the Prospect - Epic cohort
###end p 43
###begin p 44
We examined the interaction between the P12A polymorphism and risk factors for each of the events separately by introduction of risk factor*A12 allele carriers term in the logistic regression models. No signifi cant interactions between P12A and risk factors in AMI, CHD and total ischemic events were seen, apart from smoking (current) and A12 allele carriers (P = 0.027). In the light of the many associations we studied, this may actually be a chance fi nding.
###end p 44
###begin title 45
Meta-analysis results
###end title 45
###begin p 46
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 399 407 399 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 440 448 440 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
Table 4 shows the characteristics of studies included in this meta-analysis. The genotype frequencies in the studies were consistent with HWE. The meta-analyses did not show a signifi cant association under dominant genetic model (OR = 0.85; 95% CI, 0.61 to 1.17; p = 0.32), recessive model (OR = 1.37; 95% CI, 0.77 to 2.47; p = 0.29) and additive model (OR = 0.94; 95% CI, 0.72 to 1.25; p = 0.69) (Figure 1). Furthermore, pooled estimate (Figure 2) did not show a signifi cant association between the polymorphism and CHD, under dominant genetic model (OR = 0.99; 95% CI, 0.79 to 1.23; p = 0.92), recessive model (OR = 1.40; 95% CI, 0.94 to 2.08; p = 0.10) and additive model (OR = 1.04; 95% CI, 0.87 to 1.25; p = 0.64). There was evidence for heterogeneity under dominant and additive genetic models for MI (p = 0.002, p = 0.006) and CHD (p = 0.002, p = 0.01), respectively. To deal with heterogeneity we used random-effect model (the DerSimonian-Laird method) for pooling data. There was not evidence for signifi cant publication bias (Egger's test = 1.85; 95% CI, -4.86 to 8.56; p = 0.54).
###end p 46
###begin title 47
Meta-analyses of AMI risk under the different genetic models
###end title 47
###begin p 48
###xml 156 183 156 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Doney and colleagues (2004)</xref>
These forest plots show the overall odds ratio for 6 studies included in the meta-analysis under the dominant, recessive, and additive models respectively. Doney and colleagues (2004) did not provide data for recessive and additive models. Size of cubes represents weight of each study.
###end p 48
###begin title 49
Meta-analyses of CHD risk under the different genetic models
###end title 49
###begin p 50
###xml 156 183 156 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Doney and colleagues (2004)</xref>
These forest plots show the overall odds ratio for 9 studies included in the meta-analysis under the dominant, recessive, and additive models respectively. Doney and colleagues (2004) did not provide data for recessive and additive models. Size of cubes represents weight of each study.
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 46 51 <span type="species:ncbi:9606">women</span>
In this prospective study among healthy Dutch women aged 49 to 70 years, no statistically signifi cant association for exchanging proline with alanine in PPARG gene was seen with CHD and ischemic stroke risk under different genetic models. We found a borderline effect for AMI risk under the dominant and additive models, which could be a chance fi nding. In the meta-analyses of published observational studies we did not fi nd any signifi cant association for the polymorphism and AMI and CHD risks under different inheritance models.
###end p 52
###begin p 53
In this study, prevalent cases of CHD and cerebrovascular disease were excluded to prevent introducing bias due to potentially selective survival. The Prospect study is a population-based cohort, which makes it less susceptible to selection bias. Additional strengths are the comprehensive data and sample collection, complete hospital admission and mortality follow-up, and the case-cohort design which combines the advantages of cohort studies (multiple outcomes and time-dependent covariates) with those of case-control analyses (fewer subjects), thus being more effi cient. Since the genotypes were in the Hardy-Weinberg equilibrium, we did not have misclassifi cation of exposure (genotypes). Limitations are the relative short period of follow-up and the relative small number of cases. The latter in general reduces the power to show a statistical signifi cant relations.
###end p 53
###begin p 54
###xml 775 792 775 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Peters et al 2006</xref>
A new aspect is that we conducted meta-analyses on the relation between the P12A polymorphism and MI, CHD and ischemic stroke under different genetic models. Yet, due to the genotype frequency, its power is limited for most studies especially under recessive genetic model. The results of these meta-analyses indicate no association between the polymorphism and risk of MI and CHD under different genetic models. However it must be noted that an important issue in every meta-analysis is publication bias as negative studies are less likely to be submitted or accepted for publication, especially when this concerns smaller studies. Although publication bias was not present based on Egger's test, the performance of this test and the usual funnel plot have been challenged (Peters et al 2006) and so we can not completely rule out low probability for missing of small negative studies. Another limitation may be that our meta-analysis was based on published results and that we did not have access to original individual data. Fi nally, the case control studies included in the meta-analysis could be potentially prone to selection bias if survival post-MI varies by genotype.
###end p 54
###begin p 55
###xml 30 47 30 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Ridker et al 2003</xref>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 733 746 733 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Li et al 2006</xref>
###xml 1110 1132 1110 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Smith and Ebrahim 2004</xref>
###xml 1691 1708 1691 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Ridker et al 2003</xref>
###xml 1795 1809 1795 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Zee et al 2006</xref>
###xml 352 355 <span type="species:ncbi:9606">men</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
The Physician's Health Study (Ridker et al 2003) reported a modest protective effect of P12A polymorphism in PPARG gene for incidence of AMI among 523 individuals who subsequently developed myocardial infarction and 2092 individuals who remained free of reported cardiovascular disease in a prospective cohort of 14916 initially healthy American white men (Physician's Health Study cohort) aged 40 to 84 years over a mean follow-up period of 13.2 years. The Ala12 allele was associated with 23% reduction in myocardial infarction risk (OR 0.77; 95% CI, 0.60 to 0.98). In a recent case-control study of 844 subjects including 218 patients, increased risk of MI was seen under dominant mode of inheritance (OR 1.83; 95% CI, 1.06-3.1) (Li et al 2006). Under dominant and additive modes of inheritance we found a statistically signifi cant association (p = 0.05 and 0.03, respectively) for risk of AMI, but it must be considered that the number of AMI cases was 71. Since it has been documented that very large sample sizes are required to provide suffi ciently precise estimates of genotype-disease associations (Smith and Ebrahim 2004), the power in our study was low (under 20%) which means that the probability for having a false positive fi nding was around 80%. Therefore, we conducted a meta-analysis of 6 studies with 1739 AMI cases and 5903 controls to obtain a more precise estimate. The meta-analysis did not show a signifi cant association under dominant, recessive and additive genetic models. Moreover, in a very recent prospective population-based study of multi-locus candidate gene polymorphisms by a group of investigators who had previously published a part of their results (Ridker et al 2003), showed that neither these three polymorphisms nor the others were predictors of MI (Zee et al 2006).
###end p 55
###begin p 56
###xml 392 410 392 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Pischon et al 2005</xref>
###xml 585 602 585 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Bluher et al 2002</xref>
###xml 148 153 <span type="species:ncbi:9606">women</span>
###xml 158 161 <span type="species:ncbi:9606">men</span>
###xml 206 211 <span type="species:ncbi:9606">women</span>
###xml 252 255 <span type="species:ncbi:9606">men</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
Our fi ndings with respect to CHD are in accordance with results from Nurses' Health Study and Health Professionals Follow-up Study respectively in women and men of 245 cases of nonfatal MI or fatal CHD in women (compared with 485 controls) and 250 in men (compared with 502 controls) during 8 and 6 years of follow-up that the P12A polymorphism is not associated with decreased risk of CHD (Pischon et al 2005). In a cross-sectional study of patients with diabetes mellitus type 2 in Germany (in 201 patients with and 164 without CHD) that the A12 allele was not related to CHD risk (Bluher et al 2002). Our fi ndings and the meta analyses fi ndings agree with these fi ndings.
###end p 56
###begin p 57
###xml 117 131 117 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Lee et al 2006</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Recently, P12A polymorphism has been related to a reduced risk for ischemic stroke in patients with type 2 diabetes (Lee et al 2006). We found no association between the polymorphism and risk of occurrence of ischemic stroke under different genetic models. As these two studies are the only ones available, further studies are needed.
###end p 57
###begin p 58
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 37 42 <span type="species:ncbi:9606">women</span>
In conclusion, this study in healthy women free from previous cardiovascular disease and the meta-analyses show that, the P12A polymorphism in PPARG gene is not associated with future risk of AMI, CHD, and ischemic stroke.
###end p 58
###begin p 59
###xml 23 35 <span type="species:ncbi:9606">participants</span>
We are grateful to the participants of the Prospect-EPIC study. We thank all fi eld workers, laboratory technicians and skillful contributions to the data collection and all those who contributed to this study.
###end p 59
###begin p 60
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding</bold>
Funding Dr Zafarmand has been supported by a grant from the Iranian Ministry of Health and Medical Education (FN12265). The Prospect-EPIC study was funded by "Europe Against Cancer" Programme of the European Commission (SANCO).
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis
###end article-title 62
###begin article-title 63
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
###end article-title 63
###begin article-title 64
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus
###end article-title 64
###begin article-title 65
A multilocus genotyping assay for candidate markers of cardiovascular disease risk
###end article-title 65
###begin article-title 66
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
###end article-title 66
###begin article-title 67
Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study
###end article-title 67
###begin article-title 68
Measuring inconsistency in meta-analyses
###end article-title 68
###begin article-title 69
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology
###end article-title 69
###begin article-title 70
Quantitative synthesis in systematic reviews
###end article-title 70
###begin article-title 71
Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes
###end article-title 71
###begin article-title 72
Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population
###end article-title 72
###begin article-title 73
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis
###end article-title 73
###begin article-title 74
Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus
###end article-title 74
###begin article-title 75
Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes
###end article-title 75
###begin article-title 76
Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project
###end article-title 76
###begin article-title 77
Comparison of two methods to detect publication bias in meta-analysis
###end article-title 77
###begin article-title 78
###xml 109 112 <span type="species:ncbi:9606">men</span>
###xml 117 122 <span type="species:ncbi:9606">women</span>
Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women
###end article-title 78
###begin article-title 79
A case-cohort design for epidemiologic cohort studies and disease prevention trials
###end article-title 79
###begin article-title 80
Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction
###end article-title 80
###begin article-title 81
Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension
###end article-title 81
###begin article-title 82
Mendelian randomization: prospects, potentials, and limitations
###end article-title 82
###begin article-title 83
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis
###end article-title 83
###begin article-title 84
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study
###end article-title 84
###begin article-title 85
Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations
###end article-title 85
###begin article-title 86
Effect of the PPAR gamma2 Pro12Ala polymorphism on the risk of myocardial infarction
###end article-title 86
###begin article-title 87
Role of peroxisome proliferator-activated receptors in infl ammation control
###end article-title 87
###begin article-title 88
###xml 25 27 22 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3-</sub>
T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: a case-cohort study and meta-analysis
###end article-title 88
###begin article-title 89
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis
###end article-title 89
###begin p 90
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Declaration of interests</bold>
Declaration of interests Authors declare that no competing interests exist.
###end p 90

